ArticleACS medicinal chemistry letters2026
A Dual-Action Gold(I) Prodrug Targeting Redox Homeostasis and Extracellular Matrix Remodeling in Ovarian Cancer.
Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multifunctional auranofin analogues: dual-targeting TSPO/TrxR gold(I) complexes with activity in resistant ovarian cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is characterized by early metastatic dissemination, frequent relapses, and limited therapeutic options following the onset of platinum resistance. To address these challenges, a dual-action gold-(I) prodrug, RDL-15, was designed to concurrently interfere with intracellular redox regulation and extracellular matrix remodeling. RDL-15 combines the gold-(I) pharmacophore derived from Auranofin with the scaffold of LP-158, a carboxylate-based inhibitor of gelatinases MMP-2 and MMP-9 previously described. The complex retains micromolar cytotoxic activity in ovarian cancer cell lines A2780 and SKOV-3, including the cisplatin and AF-resistant A2780/R variant, and induces an early reduction of thioredoxin reductase activity. In SKOV-3 cells, characterized by high migratory and invasive capacity, RDL-15 significantly suppresses migration and invasion, whereas Et
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.